Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Anal canal squamous cell carcinoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Anal canal squamous cell in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Vitelliform Macular Dystrophy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Vitelliform Macular Dystrophy in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Ichthyosis Bullosa of Siemens Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Ichthyosis Bullosa of Siemens in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Glomerulonephritis, IGA Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Glomerulonephritis, IGA in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Macular Degeneration, Age-Related, 3 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Macular Degeneration in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Tuberculosis, Endocrine Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Tuberculosis, Endocrine in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Oroticaciduria 1 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Oroticaciduria 1 with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Nephrotic Syndrome, Idiopathic, Steroid-Resistant Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Nephrotic Syndrome in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Alopecia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Alopecia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Empyema, Pleural Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Empyema, Pleural with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Signet Ring Cell Carcinoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Signet Ring Cell Carcinoma in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Ectodermal Dysplasia 1, Anhidrotic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Ectodermal Dysplasia 1 in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..